Key statistics
On Thursday, Satellos Bioscience Inc (MSCL:TOR) closed at 15.35, -9.71% below its 52-week high of 17.00, set on Feb 04, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 15.99 |
|---|---|
| High | 16.20 |
| Low | 15.25 |
| Bid | -- |
| Offer | -- |
| Previous close | 15.77 |
| Average volume | 41.86k |
|---|---|
| Shares outstanding | 20.63m |
| Free float | 14.18m |
| P/E (TTM) | -- |
| Market cap | 317.39m CAD |
| EPS (TTM) | -2.30 CAD |
Data delayed at least 15 minutes, as of Feb 12 2026 20:59 GMT.
More ▼
Press releases
- Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
- Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
- Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
- Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
- Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
- Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
- Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos to Participate in December Investor Conferences
- Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
More ▼
